Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Plant-Derived Extracellular Vesicles in Dermatology: A Review of Emerging Therapeutic Applications

Burshtein J., Wei J., Majewska L., Schlesinger T.

Narrative Review on Chronic Wound, Scar, Immune Modulation, published in J Clin Aesthet Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Clin Aesthet Dermatol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41890780
PMCID
PMC13016450

Abstract (original English)

Objective This article aims to evaluate and discuss the therapeutic potential of plant-derived extracellular vesicles (PEVs) in clinical and aesthetic dermatology by examining their mechanisms, clinical application, efficacy, and safety profiles. Methods A comprehensive literature search was completed using the keywords "plant-derived exosomes," "dermatology," "skin disorders," "treatment," "inflammatory skin conditions," "cosmetic," "regenerative medicine," "wound healing," and "chemotherapeutic skin-related toxicities." The authors reviewed all studies and included those that addressed PEVs. Results PEVs demonstrate multifaceted therapeutic properties: (1) immunomodulation through suppression of proinflammatory cytokines (interleukin 17, tumor necrosis factor-α), (2) restoration of skin barrier function, (3) promotion of tissue regeneration in wounds and scars, and (4) effective stabilization and delivery of therapeutic cargo (microRNAs, hydrophobic drugs). Clinical case studies, particularly with rose stem cell exosomes, show efficacy in atopic dermatitis, psoriasis, wound healing, and chemotherapy-induced dermatologic toxicities, with rapid symptom relief and structural improvement. Limitations Current evidence is constrained by predominance of preclinical data focused primarily on mammalian-derived exosomes as well as variability in PEV isolation and characterization metho

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research